article thumbnail

DEA Delays Production Of Marijuana Drug As Potential Treatment For MS And Huntington’s Disease

The Fresh Toast

DEA Delays Production Of Marijuana Drug As Potential Treatment For MS And Huntington’s Disease. The DEA application process is being delayed for years for reasons unknown. The post DEA Delays Production Of Marijuana Drug As Potential Treatment For MS And Huntington’s Disease appeared first on The Fresh Toast.

DEA 84
article thumbnail

USA: Dr Suing DEA Over Right To Give Patients Psilocybin Treatment

Cannabis Law Report

The post USA: Dr Suing DEA Over Right To Give Patients Psilocybin Treatment first appeared on Cannabis Law Report. Marijuana Moment reports A Seattle doctor hoping to expand access to psilocybin mushrooms for terminally ill cancer patients is taking… Read More.

DEA 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine.

DEA 98
article thumbnail

Court: DEA Must Explain Its Failure to Act Upon Pending Marijuana Cultivation Applications

NORML

” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. Read NORML’s new op-ed, “Three years ago the DEA said they would remove roadblocks to cannabis research — they still haven’t, here.).

DEA 216
article thumbnail

Hemp Trade Association, Seller Lose Legal Challenge to DEA Rule

Cannabis Law Report

Only appeals courts may hear challenges to DEA determinations, findings, and conclusions under the Controlled Substances Act, Judge Karen LeCraft Henderson of the US Court of Appeals for the D.C. The DEA in August 2020 issued a rule meant to conform existing regulations to amendments to the CSA in its treatment of hemp.

DEA 52
article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

The FDA’s approval of the drug is just one step toward getting Epidiolex on the market and available to doctors to prescribe as a treatment option. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. View original article.

DEA 52